Drug Target Review

Skip to main content
Skip to navigation

Featured content

Turning CRISPR hits into confident drug discovery decisions

2026-05-07T12:30:00+01:00By Dr Salman Tamaddon-Jahromi

Functional genomics is central to modern drug discovery, yet high attrition rates persist. In this article, Dr Salman Tamaddon-Jahromi, a postdoctoral research associate at the University of Cambridge, discusses how end-to-end CRISPR screening strategies, iPSC-derived neuronal models and layered quality control can convert functional genomics signals into actionable therapeutic hypotheses.

Article
The scale divide: competing strategies in AI drug discovery
2026-05-04T07:00:00+01:00By Dr Raminderpal Singh
Two approaches to AI in preclinical drug discovery are diverging, from multi-thousand GPU systems to models with only a handful of parameters, with early results raising questions about which will deliver.
Article
When scale meets insight: reinventing SPR for the future of drug discovery
2026-04-30T09:08:00+01:00By Carterra
Carterra’s new 48-channel SPR platform reimagines throughput, automation and data quality for modern discovery workflows.
Article
Drug Target Review launches new website designed for drug discovery professionals
2026-04-30T07:00:00+01:00
Drug Target Review has launched an updated website to improve access to content across early-stage drug discovery, alongside a new membership model that provides full access to premium analysis, reports and expert commentary.

Opinion and interviews

Computational design drives new generation of synthetic promoters

2026-03-26T14:21:00+00:00By Drug Target Review

Designing gene control from scratch is becoming possible. SynGenSys is using computational design to create synthetic promoters for advanced therapies.

Previous
Next

Webinars

Previous
Next

Whitepapers

Previous
Next

Transform your drug discovery pipeline with 3D cellular models